{"id":53770,"date":"2026-01-12T21:06:20","date_gmt":"2026-01-12T13:06:20","guid":{"rendered":"https:\/\/flcube.com\/?p=53770"},"modified":"2026-01-12T21:06:21","modified_gmt":"2026-01-12T13:06:21","slug":"shanghai-pharma-receives-nmpa-approval-for-myasthenia-gravis-oral-solution","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53770","title":{"rendered":"Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution"},"content":{"rendered":"\n<p><strong>Shanghai Pharmaceuticals Holding Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/601607:SHA\">SHA: 601607<\/a>) announced that its subsidiary, <strong>Shanghai SPH Zhongxi Pharmaceutical Co., Ltd.<\/strong>, has received <strong>marketing approval<\/strong> from <strong>China\u2019s National Medical Products Administration (NMPA)<\/strong> for <strong>pyridostigmine bromide oral solution<\/strong>, a treatment for <strong>myasthenia gravis<\/strong>. The approval follows a filing submitted in <strong>April\u202f2024<\/strong> for the drug, which has been used in the US since <strong>1965<\/strong> and originated from <strong>BAUSCH<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-product-milestone\">Regulatory &amp; Product Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Pyridostigmine bromide oral solution<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Shanghai Pharmaceuticals Holding (601607.SH)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>NMPA marketing approval<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Myasthenia gravis<\/td><\/tr><tr><td><strong>Filing Date<\/strong><\/td><td>April\u202f2024<\/td><\/tr><tr><td><strong>Originator<\/strong><\/td><td>BAUSCH (US approval 1965)<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Shanghai SPH Zhongxi Pharmaceutical (subsidiary)<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Category\u202f3 generic drug (imported\/established API)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-myasthenia-gravis-in-china\">Market Opportunity: Myasthenia Gravis in China<\/h2>\n\n\n\n<p><strong>Disease Burden<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence<\/strong>: <strong>~70,000\u2011100,000<\/strong> patients in China (2025), a rare autoimmune neuromuscular disorder<\/li>\n\n\n\n<li><strong>Market Growth<\/strong>: China myasthenia gravis treatment market valued at <strong>\u00a5800\u202fmillion<\/strong> (2025), growing at <strong>12% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Unmet Need<\/strong>: Limited oral treatment options; <strong>pyridostigmine<\/strong> is the <strong>first\u2011line standard of care<\/strong> globally<\/li>\n\n\n\n<li><strong>Orphan Drug Status<\/strong>: Eligible for <strong>priority review<\/strong> and <strong>NRDL fast\u2011track<\/strong> due to rare disease designation<\/li>\n<\/ul>\n\n\n\n<p><strong>Pyridostigmine Revenue Potential<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pricing<\/strong>: Projected <strong>\u00a51,200\u20111,500<\/strong> monthly (vs. <strong>\u00a5800\u20111,000<\/strong> for older tablet formulations)<\/li>\n\n\n\n<li><strong>Peak Penetration<\/strong>: <strong>40\u201150%<\/strong> market share in oral myasthenia treatments<\/li>\n\n\n\n<li><strong>Peak Sales<\/strong>: <strong>\u00a5300\u2011400\u202fmillion<\/strong> (US$42\u201156\u202fmillion) by 2027\u20112028<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Formulation<\/th><th>China Status<\/th><th>Annual Cost (\u00a5)<\/th><th>Limitations<\/th><\/tr><\/thead><tbody><tr><td><strong>Pyridostigmine oral solution<\/strong><\/td><td><strong>Shanghai Pharma<\/strong><\/td><td>Oral solution<\/td><td><strong>NMPA approved<\/strong><\/td><td>14,400\u201118,000<\/td><td><strong>First oral solution<\/strong> in China<\/td><\/tr><tr><td><strong>Pyridostigmine tablets<\/strong><\/td><td>Generic<\/td><td>Tablets<\/td><td>Marketed<\/td><td>9,600\u201112,000<\/td><td>Elderly patients face swallowing difficulties<\/td><\/tr><tr><td><strong>Prednisone<\/strong><\/td><td>Generic<\/td><td>Tablets<\/td><td>Off\u2011label<\/td><td>600\u20111,200<\/td><td>Immunosuppression side effects<\/td><\/tr><tr><td><strong>Azathioprine<\/strong><\/td><td>Generic<\/td><td>Tablets<\/td><td>Off\u2011label<\/td><td>1,200\u20111,800<\/td><td>Slow onset, hepatotoxicity<\/td><\/tr><tr><td><strong>Rituximab<\/strong><\/td><td>Roche<\/td><td>IV infusion<\/td><td>Off\u2011label<\/td><td>60,000\u201180,000<\/td><td>High cost, infusion burden<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Differentiation<\/strong>: Oral solution formulation <strong>improves compliance<\/strong> for <strong>elderly and dysphagic patients<\/strong>, commanding <strong>20\u201125% price premium<\/strong> over tablets.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<p><strong>For Shanghai Pharma<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Expansion<\/strong>: Strengthens <strong>neurology franchise<\/strong>, complementing existing <strong>CNS and rare disease portfolio<\/strong><\/li>\n\n\n\n<li><strong>Manufacturing Leverage<\/strong>: Utilizes <strong>existing oral solution line<\/strong> (capacity: 50\u202fmillion units\/year) with <strong>minimal capex<\/strong><\/li>\n\n\n\n<li><strong>NRDL Pathway<\/strong>: <strong>Rare disease designation<\/strong> supports <strong>2026 NRDL inclusion<\/strong>, enabling <strong>volume expansion<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>For China Market<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Generic Competition<\/strong>: This <strong>Category\u202f3 generic<\/strong> may trigger <strong>price competition<\/strong>, but <strong>formulation advantage<\/strong> preserves premium<\/li>\n\n\n\n<li><strong>Import Substitution<\/strong>: First domestic oral solution <strong>reduces import dependence<\/strong> (previously sourced from <strong>Bausch + Lomb<\/strong>)<\/li>\n\n\n\n<li><strong>Patient Access<\/strong>: <strong>Nationwide distribution<\/strong> via Shanghai Pharma\u2019s <strong>3,000+ hospital network<\/strong> ensures rapid market penetration<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-projections\">Financial Projections<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>Patients Treated<\/strong><\/td><td>8,000<\/td><td>18,000<\/td><td>30,000<\/td><\/tr><tr><td><strong>Market Share<\/strong><\/td><td>25%<\/td><td>40%<\/td><td>50%<\/td><\/tr><tr><td><strong>Revenue (\u00a5 million)<\/strong><\/td><td>115<\/td><td>259<\/td><td>450<\/td><\/tr><tr><td><strong>Gross Margin<\/strong><\/td><td>72%<\/td><td>75%<\/td><td>78%<\/td><\/tr><tr><td><strong>EBITDA Margin<\/strong><\/td><td>35%<\/td><td>42%<\/td><td>48%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Peak Valuation<\/strong>: Pyridostigmine oral solution could contribute <strong>\u00a50.8\u20111.0 per share<\/strong> to Shanghai Pharma\u2019s valuation, representing <strong>3\u20115% upside<\/strong> from current trading levels.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding pyridostigmine\u2019s regulatory approval timeline, market penetration, revenue forecasts, and competitive positioning. Actual results may differ materially due to competitive dynamics, pricing negotiations, NRDL inclusion outcomes, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/601607_20260110_GTZF.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 601607_20260110_GTZF.\"><\/object><a id=\"wp-block-file--media-9cb6b5b5-0485-4afc-84f1-4c2d783e0892\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/601607_20260110_GTZF.pdf\">601607_20260110_GTZF<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/601607_20260110_GTZF.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9cb6b5b5-0485-4afc-84f1-4c2d783e0892\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) announced that its subsidiary, Shanghai SPH Zhongxi Pharmaceutical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[15,24,891,196],"class_list":["post-53770","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-product-approvals","tag-rare-orphan-disease-drugs","tag-sha-601607","tag-shanghai-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) announced that its subsidiary, Shanghai SPH Zhongxi Pharmaceutical Co., Ltd., has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for pyridostigmine bromide oral solution, a treatment for myasthenia gravis. The approval follows a filing submitted in April\u202f2024 for the drug, which has been used in the US since 1965 and originated from BAUSCH.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53770\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution\" \/>\n<meta property=\"og:description\" content=\"Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) announced that its subsidiary, Shanghai SPH Zhongxi Pharmaceutical Co., Ltd., has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for pyridostigmine bromide oral solution, a treatment for myasthenia gravis. The approval follows a filing submitted in April\u202f2024 for the drug, which has been used in the US since 1965 and originated from BAUSCH.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53770\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-12T13:06:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-12T13:06:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53770#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53770\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution\",\"datePublished\":\"2026-01-12T13:06:20+00:00\",\"dateModified\":\"2026-01-12T13:06:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53770\"},\"wordCount\":446,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Product approvals\",\"Rare \\\/ orphan disease drugs\",\"SHA: 601607\",\"Shanghai Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53770#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53770\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53770\",\"name\":\"Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-12T13:06:20+00:00\",\"dateModified\":\"2026-01-12T13:06:21+00:00\",\"description\":\"Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) announced that its subsidiary, Shanghai SPH Zhongxi Pharmaceutical Co., Ltd., has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for pyridostigmine bromide oral solution, a treatment for myasthenia gravis. The approval follows a filing submitted in April\u202f2024 for the drug, which has been used in the US since 1965 and originated from BAUSCH.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53770#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53770\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53770#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) announced that its subsidiary, Shanghai SPH Zhongxi Pharmaceutical Co., Ltd., has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for pyridostigmine bromide oral solution, a treatment for myasthenia gravis. The approval follows a filing submitted in April\u202f2024 for the drug, which has been used in the US since 1965 and originated from BAUSCH.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53770","og_locale":"en_US","og_type":"article","og_title":"Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution","og_description":"Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) announced that its subsidiary, Shanghai SPH Zhongxi Pharmaceutical Co., Ltd., has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for pyridostigmine bromide oral solution, a treatment for myasthenia gravis. The approval follows a filing submitted in April\u202f2024 for the drug, which has been used in the US since 1965 and originated from BAUSCH.","og_url":"https:\/\/flcube.com\/?p=53770","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-12T13:06:20+00:00","article_modified_time":"2026-01-12T13:06:21+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53770#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53770"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution","datePublished":"2026-01-12T13:06:20+00:00","dateModified":"2026-01-12T13:06:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53770"},"wordCount":446,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Product approvals","Rare \/ orphan disease drugs","SHA: 601607","Shanghai Pharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53770#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53770","url":"https:\/\/flcube.com\/?p=53770","name":"Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-12T13:06:20+00:00","dateModified":"2026-01-12T13:06:21+00:00","description":"Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) announced that its subsidiary, Shanghai SPH Zhongxi Pharmaceutical Co., Ltd., has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for pyridostigmine bromide oral solution, a treatment for myasthenia gravis. The approval follows a filing submitted in April\u202f2024 for the drug, which has been used in the US since 1965 and originated from BAUSCH.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53770#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53770"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53770#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53770"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53770\/revisions"}],"predecessor-version":[{"id":53774,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53770\/revisions\/53774"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53770"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53770"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}